PREDICT-SpA: Evaluating the influence of gender on disease assessment tools Dr. Sheila Reyes reports on abstract 0571, Gender-specific Performance of Disease Activity Assessment Tools in Axial Spondyloarthritis: Ancillary Analysis of the PREDICT-SpA Study, presented at #ACR24.… https://t.co/EGlCap6pEw

Among axSpA patients enrolled in the BE MOBILE 1&2, those who received Bimekizumab achieved ASAS40 response earlier vs PBO Improvements in spinal pain and physical function were significantly reported as early as wk 1 in those who received BKZ vs PBO @RheumNow #ACR24 abs2363 https://t.co/JmcQdURTY4

• https://x.com/RHEUMarampa/status/1858613336788574630/photo/1
• https://x.com/RHEUMarampa/status/1858613336788574630/photo/1

SEC demonstrated high retention rates after 5 years in pts with PsA and r-axSpA in this real-world study. Reasons for stopping SEC: lack of efficacy pt decision lost to ffup AEs Reassuring data on SECs position in the treatment of PsA/AS. @Rheumnow #ACR24 abs2344 https://t.co/zECEsheQIi

• https://x.com/RHEUMarampa/status/1858580860238217419/photo/1

A#2583 Apremilast for axial inflamm in PsA, assess by CANDEN MRI scoring MOSAIC P4 open label trial Reduction in inflammation seen in vertebral bodies & posteriolateral, not in facet joints No changes in SPARCC SIJ, spine - though low baseline SIJ inflammation @RheumNow #ACR24 https://t.co/3GKEGJbtdc

• https://x.com/ericdeinmd/status/1858581617067127217/photo/1

A systematic review & meta-analysis by Dr. JBCorrea et al show that the ff immune-mediated dses are assocd w/⬆️ ocurrence risk after covid19 infection 👇 Behcets SpA SS SLE PMR Pso RA Sjogrens T1DM Vasculitis IBD Ask prior covid infexn in pts history @RheumNow #ACR24 abs2614 https://t.co/TIEglPrmvL

• https://x.com/RHEUMarampa/status/1858590128110784622/photo/1

A higher number of axSpA pts enrolled in BE MOBILE 1&2 who were treated with BKZ achieved remission accdg to the OSI vs. ASDAS ID (40.5% vs 15.2%) at wk 16 until wk 52. OSI a better measure of remission? @RheumNow #ACR24 abs2362 https://t.co/GCHjXQi9S9

• https://x.com/RHEUMarampa/status/1858595035559932201/photo/1

Sharma @Amansharmapgi et al. DADA2. Clinical manifestations of 101(!) patients. @RheumNow #ACR24 Abstr#2647 https://t.co/Tkk6Rz6rtT https://t.co/frvFPYy4xf

• Clinical Characteristics , Treatment Outcomes and Predictors of Mortality in a …
• https://x.com/RichardPAConway/status/1858603584356774002/photo/1

Reproductive Issues in axSpA: Fertility and Pregnancy axSpA affects young patients with symptom onset occurring in early adulthood. Apart from pain and quality of life, reproductive issues also arise because patients who are diagnosed with the disease are also in their… https://t.co/8tLFOvFqdO https://t.co/E3AOOCHTgu

Low uveitis rates in patients with axial spondyloarthritis and psoriatic arthritis treated with bimekizumab (BKZ) over the long term. Key findings: - AxSpA: 3.7% incidence (1.3/100 PY) with BKZ. - PsA: Only 0.2% incidence (0.1/100 PY). - All events were mild/moderate, with no… https://t.co/jkUwHJk3FJ https://t.co/gTcCzeC88e

• https://x.com/i/web/status/1858536895019438208
• https://x.com/synovialjoints/status/1858536895019438208/photo/1